Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
79 hedge funds and large institutions have $412M invested in Repros Therapeutics Inc. in 2013 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 24 reducing their positions, and 26 closing their positions.
50% more call options, than puts
Call options by funds: $17.7M | Put options by funds: $11.8M
29% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 24
14% less funds holding
Funds holding: 92 → 79 (-13)
29% less capital invested
Capital invested by funds: $577M → $412M (-$166M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
50% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$19M |
| 2 |
State Street
Boston,
Massachusetts
|
+$17.8M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$14.9M |
| 4 |
PC
PointState Capital
New York
|
+$5.1M |
| 5 |
Jennison Associates
New York
|
+$4.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$26.6M |
| 2 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$12.3M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$11.7M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.9M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.06M |
RPRX Hedge Fund Activity: Q4 2013 in Review
79 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q4 2013, worth a combined $412M — down 29% from $577M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of RPRX and 13 opened new positions — a net loss of 13 holders — while 24 trimmed existing stakes and 31 added.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $19M. The largest seller was Perceptive Advisors, cutting an estimated $26.6M.
- 79 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q4 2013, down from 92 in Q3 2013.
- Funds reported $412M of Repros Therapeutics Inc. stock for Q4 2013, down 29% quarter-over-quarter.
- 13 funds opened new Repros Therapeutics Inc. positions in Q4 2013 and 26 closed out, a net change of -13 holders.
- The largest Repros Therapeutics Inc. buyer in Q4 2013 was Fidelity Investments, an estimated $19M added.
- The largest Repros Therapeutics Inc. seller in Q4 2013 was Perceptive Advisors, an estimated $26.6M sold.
Based on aggregated 13F filings for Q4 2013.